# EDGAR Filing Document

**Accession Number:** 0001029125
**File Stem:** 0001437749-23-007117
**Filing Date:** 2023-3
**Character Count:** 14383
**Document Hash:** b5c1bf5d19f6e5e3f6974f72c313935d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-007117.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0001437749-23-007117

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**REFERENCES 429**: 333-239186

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230317

**EFFECTIVENESS DATE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Panbela Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001029125
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 870543922
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270685
- **FILM NUMBER:** 23744197

**BUSINESS ADDRESS:**
- **STREET 1:** 712 VISTA BLVD #305
- **CITY:** WACONIA
- **STATE:** MN
- **ZIP:** 55387
- **BUSINESS PHONE:** 9524791196

**MAIL ADDRESS:**
- **STREET 1:** 712 VISTA BLVD #305
- **CITY:** WACONIA
- **STATE:** MN
- **ZIP:** 55387

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sun BioPharma, Inc.
- **DATE OF NAME CHANGE:** 20150911

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cimarron Medical, Inc.
- **DATE OF NAME CHANGE:** 20150602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CIMARRON SOFTWARE INC
- **DATE OF NAME CHANGE:** 19961217

**As filed with the Securities and Exchange Commission on March 17, 2023.**

**Registration No. 333**-

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**Form S-8**

**REGISTRATION STATEMENT UNDER THE**

**SECURITIES ACT OF 1933**

---

| |
|:---|
| **PANBELA THERAPEUTICS, INC.**  |
| (Exact Name of Registrant as Specified in its Charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **88-2805017** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |
| **712 Vista Blvd #305** <br> **Waconia, MN** | **55387** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**2016 Omnibus Incentive Plan**

(Full Title of the Plan)

**Susan Horvath**<br> Chief Financial Officer<br> Panbela Therapeutics, Inc.<br> 712 Vista Blvd #305<br> Waconia, MN 55387<br> (Name and Address of Agent for Service)<br>

Telephone number, including area code, of agent for service: **(952) 479-1196**

------

Copies to:

**W. Morgan Burns**

**Joshua L. Colburn**

Faegre Drinker Biddle & Reath LLP

2200 Wells Fargo Center

90 South Seventh Street

Minneapolis, Minnesota 55402-3901

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ Accelerated Filer ☐ <br> Non-accelerated Filer ☑ Smaller Reporting Company ☑ <br> Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**PANBELA THERAPEUTICS, INC.**

**STATEMENT PURSUANT TO GENERAL INSTRUCTION E**<br> **TO FORM S-8** "**REGISTRATION OF ADDITIONAL SECURITIES**"

The stockholders of Panbela Therapeutics, Inc., (the "Company") initially approved the Company's 2016 Omnibus Incentive Plan on May 17, 2016. On May 19, 2020, the stockholders of the Company approved an amendment and restatement of the Company's 2016 Omnibus Incentive Plan (as amended and restated, the "2016 Plan"). The 2016 Plan provides, among other things, that the number of shares of the Company's common stock available for issuance under the plan will increase on January 1 of each year beginning in 2021 and ending on January 1, 2025 in an amount equal to the lesser of (i) the number of shares necessary to increase the total option pool to 20% of the total number of fully diluted shares (as defined in the 2016 Plan) as of December 31 of the immediately preceding calendar year and (ii) such lesser number of shares as may be determined by the Company's Board of Directors or its Compensation Committee prior to January 1st of any calendar year.

On June 15, 2020, Panbela Research Inc. (formerly known as Panbela Therapeutics, Inc., the "Predecessor") filed a registration statement on Form S-8 (file no. 333-239186, the "Initial Registration Statement") with the Securities and Exchange Commission to register shares of the Company's common stock, $0.001 par value per share ("Common Stock"), for issuance under the 2016 Plan. Effective June 15, 2022, the Predecessor completed a corporate reorganization pursuant to which the Predecessor became a direct, wholly-owned subsidiary of the Company and the Company assumed all rights and obligations with respect to the Predecessor's equity incentive plans, including the 2016 Plan and all outstanding awards thereunder.

Pursuant to General Instruction E to Form S-8, the contents of the Initial Registration Statement, together with all exhibits filed therewith or incorporated therein by reference, are incorporated herein by reference.

The Company has filed this registration statement on Form S-8 to register the 256,955 additional shares of Common Stock, not previously registered under the 2016 Plan, that became available for issuance under the 2016 Plan effective as of January 1, 2023.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description of Exhibit** |
| 4.1 | [Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to current report on Form 8-K filed January 17, 2023).](http://www.sec.gov/Archives/edgar/data/1029125/000143774923001167/ex_464424.htm) |
| 4.2 | [Bylaws (incorporated by reference to Exhibit 3.1 to current report on Form 8-K filed June 16, 2022)](http://www.sec.gov/Archives/edgar/data/1029125/000143774922015110/ex_387261.htm) |
| 5.1+ | [Opinion of Faegre Drinker Biddle & Reath LLP](ex_490021.htm) |
| 23.1+ | [Consent of Independent Registered Public Accounting Firm (Cherry Bekaert LLP)](ex_490022.htm) |
| 23.2+ | [Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1)](ex_490021.htm) |
| 24 | [Powers of Attorney (included with signatures)](#poa) |
| 99.1 | [2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to current report on Form 8-K filed May 26, 2020)](http://www.sec.gov/Archives/edgar/data/1029125/000143774920011719/ex_187936.htm) |
| 107+ | [Filing Fee Table](ex_489957.htm) |

---

------

+ Filed herewith

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, State of Minnesota, on March 17, 2023.

---

| | |
|:---|:---|
| **PANBELA THERAPEUTICS, INC.** | **PANBELA THERAPEUTICS, INC.** |
| By: | /s/ Jennifer K. Simpson |
|  | Name: Jennifer K. Simpson |
|  | Title: President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below hereby constitutes and appoints Jennifer K. Simpson and Susan Horvath, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Registration Statement filed herewith and any and all amendments to said Registration Statement (including post-effective amendments), and file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on March 17, 2023:

---

| | |
|:---|:---|
| **Signature** | **Title** |
| /s/ Jennifer K. Simpson | President and Chief Executive Officer |
| Jennifer K. Simpson | (*principal executive officer*) |
| /s/ Susan Horvath | Vice President of Finance, Chief Financial Officer, Treasurer and Secretary |
| Susan Horvath | (*principal financial and accounting officer*) |
| /s/ Michael T. Cullen | Executive Chairman and Director |
| Michael T. Cullen |  |
| /s/ Daniel J. Donovan | Director |
| Daniel J. Donovan |  |
| /s/ Arthur J. Fratamico | Director |
| Arthur J. Fratamico |  |
| /s/ Jeffrey E. Jacob | Director |
| Jeffrey E. Jacob |  |
| /s/ Jeffrey S. Mathiesen | Director |
| Jeffrey S. Mathiesen |  |
| /s/ D. Robert Schemel | Director |
| D. Robert Schemel |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![alogo.jpg](alogo.jpg) | faegredrinker.com |
|  | **Faegre Drinker Biddle & Reath LLP**<br> 2200 Wells Fargo Center<br> 90 South Seventh Street<br> Minneapolis, Minnesota 55402<br> +1 612 766 7000 main<br> +1 612 766 1600 fax |

---

March 17, 2023

Panbela Therapeutics, Inc.

712 Vista Boulevard #305

Waconia, MN 55387

Ladies and Gentlemen:

In connection with the proposed registration under the Securities Act of 1933, as amended (the "Act"), of shares of Common Stock of Panbela Therapeutics, Inc., a Delaware corporation (the "Company"), offered and to be offered pursuant to the Company's 2016 Omnibus Incentive Plan (the "Plan"), we have examined the Company's Certificate of Incorporation, as amended, its Amended and Restated By-Laws and such other documents, including the Registration Statement on Form S-8 of even date herewith, to be filed with the Securities and Exchange Commission (the "Commission") relating to such shares (the "Registration Statement"), and have reviewed such matters of law as we have deemed necessary for this opinion.

Accordingly, based upon the foregoing, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Company has duly authorized the issuance of the shares of Common Stock which may be issued pursuant to the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The shares that may be issued pursuant to the Plan will be, upon issuance in accordance with the Plan, validly issued and outstanding and fully paid and nonassessable.

We consent to the filing of this opinion as an exhibit to the Registration Statement and the reference to our firm in the Registration Statement. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission.

This opinion is furnished to you in connection with the filing of the Registration Statement, and is not to be used, circulated, quoted or otherwise relied upon for any other purpose.

---

| | |
|:---|:---|
| Very truly yours,<br>FAEGRE DRINKER BIDDLE & REATH LLP | Very truly yours,<br>FAEGRE DRINKER BIDDLE & REATH LLP |
| By:  | /s/ Joshua L. Colburn |
|  | Joshua L. Colburn |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 16, 2023, relating to the consolidated financial statements of Panbela Therapeutics, Inc. (the "Company") and its subsidiaries, as of and for the year ended December 31, 2022.

*/s/ Cherry Bekaert LLP*

Tampa, Florida

March 17, 2023

## Ex-Filing

**Exhibit 107**

**Calculation of Registration Fee**

**FORM S-8**

(Form Type)

**PANBELA THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Security**<br> **Type** | **Security Class Title** | **Fee<br> Calculation**<br> **Rule** | **Amount**<br> **Registered<sup>(1)</sup>** | **Maximum**<br> **Aggregate**<br> **Offering Price** | **Fee Rate** | **Amount of**<br> **Registration**<br> **Fee** |
| Equity | Common stock, par value $0.001 per share | Rule 457(c) and<br> Rule 457(h) | 256955<sup>(2)</sup><br>$0.690<sup>(3)</sup> | $177299 | 0.0001102 | $19.54 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | 256955 | $177299 |  | $19.54 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | <sup>—(4)</sup> |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | $19.54 |

---

(1) In accordance to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover an indeterminate number of shares of Common Stock to be offered or issued from stock splits, stock dividends or similar transactions.

(2) Represents shares of common stock reserved for issuance for future awards under the Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan pursuant to such plan's evergreen provision

(3) Estimated in accordance with Rule 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registrant's registration fee on the basis of $0.690 per share, which is the average of the high and low prices of the Registrant's common stock, as reported on The Nasdaq Capital Market, on March 14, 2023, which is within 5 business days prior to filing this registration statement.

(4) The registrant does not have any fee offsets.